Alexion Pharmaceuticals (Alexion Pharmaceuticals) Interest Expense : $-106 Mil (TTM As of Mar. 2021)

View and export this data going back to 1996. Start your Free Trial

What is Alexion Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Alexion Pharmaceuticals's interest expense for the three months ended in Mar. 2021 was $ -27 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2021 was $-106 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Alexion Pharmaceuticals's Operating Income for the three months ended in Mar. 2021 was $ 826 Mil. Alexion Pharmaceuticals's Interest Expense for the three months ended in Mar. 2021 was $ -27 Mil. Alexion Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2021 was 30.48. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Alexion Pharmaceuticals Interest Expense Historical Data

The historical data trend for Alexion Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alexion Pharmaceuticals Interest Expense Chart

Alexion Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Interest Expense

Get a 7-Day Free Trial

-96.90

-98.40

-98.20

-77.80

-104.70

Alexion Pharmaceuticals Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Interest Expense	Get a 7-Day Free Trial															-25.80	-23.60	-27.60	-27.70	-27.10

Alexion Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-106 Mil.

Alexion Pharmaceuticals (NAS:ALXN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Alexion Pharmaceuticals's Interest Expense for the three months ended in Mar. 2021 was $-27 Mil. Its Operating Income for the three months ended in Mar. 2021 was $826 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2021 was $2,560 Mil.

Alexion Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2021 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2021 )	/	Interest Expense (Q: Mar. 2021 )
	=	-1	*	825.9	/	-27.1
	=	30.48

The higher the ratio, the stronger the company's financial strength is.

Alexion Pharmaceuticals (Alexion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alexion Pharmaceuticals Inc (NAS:ALXN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Seaport Boulevard, Boston, MA, USA, 02210

Website

https://www.alexion.com

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.

Executives

Daniel Bazarko	officer: SVP, Controller, CAO	C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD BOSTON MA 02210
Tanisha Carino	officer: EVP & CCAO	C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210
Anne-marie Law	officer: EVP, Chief Experience Officer	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Brian Goff	officer: EVP & Chief Commercial Officer	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John J Orloff	officer: EVP, Research & Development	C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Indrani Lall Franchini	officer: EVP, Chief Compliance Officer	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John T Mollen	director	176 SOUTH STREET HOPKINTON MA 01748
David R Brennan	director	C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Baker Bros. Advisors (gp) Llc	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Andreas Rummelt	director	C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE CHESHIRE CT 06410
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Baker Brothers Life Sciences Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Deborah Dunsire	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Judith A Reinsdorf	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974